Dr. Martens PLC — Board/Management Information 2026

May 27, 2026

National Storage Mechanism | Additional information

RNS Number : 7612F

Dr. Martens PLC

27 May 2026

27 May 2026

Dr. Martens plc

DIRECTORATE CHANGE

Dr. Martens plc ('Dr. Martens' or 'the Company'), the iconic British footwear brand with a global presence, announces that Lynne Weedall, Senior Independent Director and Chair of the Remuneration and Nomination Committees, has informed the Board of her intention to step down at the conclusion of the 2026 Annual General Meeting ('AGM') on 15 July 2026 after almost six years on the Board. Lynne will therefore not seek re-election at the 2026 AGM.

A thorough succession process to appoint Lynne's replacement on the Board is well progressed and a further announcement will be made in due course.

Paul Mason, Chairman of Dr. Martens, said: "On behalf of the Board, I would like to thank Lynne for her significant contributions since the Company's IPO in 2021. She has brought sound judgement, constructive challenge and a strong governance mindset, and I have greatly valued her counsel and support."

NOTES

1.     This announcement is made pursuant to UK Listing Rule 6.4.6R.

Enquiries

Investors and analysts                                                                       

Bethany Barnes, Director of Investor Relations and Corporate Communications

[email protected]

+44 7825 187465                                                                                                                               

Paul Rolling, Head of Secretariat

[email protected]

Press enquiries:

Rob Greening / Ludo Baynham-Herd

[email protected]

+44 207 250 1446

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.

A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections range from its Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz, and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories.

Every Dr. Martens product reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand stays as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world.

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.

For more information, visit www.drmartens.com or www.drmartensplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOASEFFIMEMSEFI